Home
Priovant Therapeutics

Priovant Therapeutics Market Share Analysis for June 2026

Priovant Therapeutics is a clinical-stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.

Industry: N/A

Domainpriovant.com

Year Founded--

Employees51 - 200

Annual Revenue--

Priovant Therapeutics

Priovant Therapeutics (including company regionals)

priovant.com

See more website traffic and engagement information

Total visits to Priovant Therapeutics's top domains

Understand Priovant Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

priovant.com14.4K

See more with Sales Intelligence

Avg. visit duration in Priovant Therapeutics's top domains

Analyze Priovant Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

priovant.com00:00:33

See more with Sales Intelligence

Avg. pageviews on Priovant Therapeutics's top domains

See how Priovant Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

priovant.com1.73

See more with Sales Intelligence

Priovant Therapeutics top competitors by domain

Top similar sites in June 2026, ranked by their affinity

immunovant.comCompany NameImmunovantEmployees201 - 500HQUnited States, New York, New York CityAnnual revenue$5M - $10MTotal visits12.2KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Priovant Therapeutics

These are the website technologies, by industry, used by Priovant Therapeutics top domains

Email Services (2)

Microsoft Exchange Online

Marketing (2)

Google Marketing Platform

Conversion & Analytics (1)

Google Analytics

Live Chat (1)

Zoom Video Conferencing

More Technologies

3

See all

News & Signals from Priovant Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPriovant Therapeutics, Inc. is developing brepocitinib for lichen planopilaris on Apr 2nd '26.On April 2, Roivant Sciences Ltd. (NASDAQ:ROIV) said its subsidiary Priovant Therapeutics had started enrolling patients in a Phase 2b/3 trial of brepocitinib for lichen planopilaris (LPP).

NewsPriovant Therapeutics, Inc. launched Phase 2b/3 clinical program for brepocitinib in lichen planopilaris on Mar 1st '26.DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) - Priovant today announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder affecting approximately 100,000 adults in the United States.

NewsPriovant Therapeutics, Inc. is developing novel therapies for autoimmune diseases with high morbidity.US-based biotech company Priovant Therapeutics is dedicated to developing novel therapies for autoimmune diseases with high morbidity and few available treatment options.